Literature DB >> 9806321

Increased vascular permeability by a specific agonist of protease-activated receptor-2 in rat hindpaw.

A Kawabata1, R Kuroda, T Minami, K Kataoka, M Taneda.   

Abstract

The present study examined the effect of intraplantar (i.pl.) administration of a selective agonist of protease-activated receptor (PAR)-2, SLIGRL-NH2(PP6-NH2), on vascular permeability in rat hindpaw. PP6-NH2, administered i.pl. at 10-100 nmol per paw, enhanced vascular permeability and caused oedema formation in rat hindpaw. SLIGRL (PP6-OH) and trypsin, by i.pl. administration, also elicited an increase in vascular permeability, although i.pl. administration of the mixture of constituent amino acids of PP6-OH at an equivalent dose did not. The PP6-NH2-induced increase in vascular permeability was abolished by repeated pretreatment with compound 48/80 to deplete bioactive amines in mast cells. These findings suggest that the activation of PAR-2 induces acute inflammation, at least partially, via mast cell degranulation in rat hindpaw.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9806321      PMCID: PMC1565636          DOI: 10.1038/sj.bjp.0702063

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  Effect of PAR2 in regulating TNF-α and NAD(P)H oxidase in coronary arterioles in type 2 diabetic mice.

Authors:  Yoonjung Park; Jiyeon Yang; Hanrui Zhang; Xiaonai Chen; Cuihua Zhang
Journal:  Basic Res Cardiol       Date:  2010-10-24       Impact factor: 17.165

Review 2.  Protease-activated receptor 2 signaling in inflammation.

Authors:  Andrea S Rothmeier; Wolfram Ruf
Journal:  Semin Immunopathol       Date:  2011-10-06       Impact factor: 9.623

3.  Activation of protease activated receptor 2 by exogenous agonist exacerbates early radiation injury in rat intestine.

Authors:  Junru Wang; Marjan Boerma; Ashwini Kulkarni; Morley D Hollenberg; Martin Hauer-Jensen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-15       Impact factor: 7.038

4.  Modulation by protease-activated receptors of the rat duodenal motility in vitro: possible mechanisms underlying the evoked contraction and relaxation.

Authors:  A Kawabata; R Kuroda; H Nishikawa; K Kawai
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

5.  Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw.

Authors:  N Vergnolle; M D Hollenberg; K A Sharkey; J L Wallace
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

6.  Effects of protease-activated receptors (PARs) on intracellular calcium dynamics of acinar cells in rat lacrimal glands.

Authors:  Makoto Oikawa; Tomoyuki Saino; Katsura Kimura; Yuki Kamada; Yasunori Tamagawa; Daijiro Kurosaka; Yoh-ichi Satoh
Journal:  Histochem Cell Biol       Date:  2013-03-06       Impact factor: 4.304

7.  Expression of protease activated receptor-2 (PAR-2) in central airways of smokers and non-smokers.

Authors:  D Miotto; M D Hollenberg; N W Bunnett; A Papi; F Braccioni; P Boschetto; F Rea; A Zuin; P Geppetti; M Saetta; P Maestrelli; L M Fabbri; C E Mapp
Journal:  Thorax       Date:  2002-02       Impact factor: 9.139

8.  A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium.

Authors:  Toshiaki Sendo; Yoshinori Itoh; Takeshi Goromaru; Tomoko Sumimura; Mami Saito; Keisei Aki; Takahisa Yano; Ryozo Oishi
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

9.  Protease activated receptors in cardiovascular function and disease.

Authors:  Junor A Barnes; Shamjeet Singh; Aldrin V Gomes
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

10.  Evidence that protease activated receptor 2 expression is enhanced in human coronary atherosclerotic lesions.

Authors:  C Napoli; F de Nigris; J L Wallace; M D Hollenberg; G Tajana; G De Rosa; V Sica; G Cirino
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.